Solid Biosciences Inc. Comprehensive Income
Solid Biosciences Inc. (SLDB) reported Comprehensive Income of -$117.22 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-03-12
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-12-31 was -$21.92M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-09-30 was -$19.02M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-06-30 was -$17.97M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-03-31 was -$15.89M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$117.22M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$74.79M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$52.15M.
- Solid Biosciences Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$21.51M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$117.22M 10-K · filed 2020-03-12 | |||
| 2018-12-31 | -$21.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$40.94M derived: sum of 2 quarters · filed 2020-03-12 | -$58.90M derived: sum of 3 quarters · filed 2020-03-12 | -$74.79M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$19.02M 10-Q · filed 2018-11-13 | -$36.98M derived: sum of 2 quarters · filed 2018-11-13 | -$52.87M 10-Q · filed 2018-11-13 | -$67.37M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$17.97M 10-Q · filed 2018-08-10 | -$33.85M 10-Q · filed 2018-08-10 | -$48.35M derived: sum of 3 quarters · filed 2020-03-12 | -$61.86M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$15.89M 10-Q · filed 2018-05-10 | -$30.38M derived: sum of 2 quarters · filed 2020-03-12 | -$43.89M derived: sum of 3 quarters · filed 2020-03-12 | -$55.20M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$28.00M derived: sum of 2 quarters · filed 2020-03-12 | -$39.32M derived: sum of 3 quarters · filed 2020-03-12 | -$52.15M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$13.51M 10-Q · filed 2018-11-13 | -$24.82M derived: sum of 2 quarters · filed 2018-11-13 | -$37.66M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$11.31M 10-Q · filed 2018-08-10 | -$24.15M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$12.84M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$21.51M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |